Is chronic fatigue syndrome an autoimmune disorder of endogenous neuropeptides, exogenous infection and molecular mimicry?

Medical Hypotheses

Volumn 62, Issue 5, 2004, Pages 646-652

  Staines, Donald R ^a  

^a Gold Coast Public Health Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADENOSINE; GLUCAGON; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INSULIN; NEUROPEPTIDE; NITRIC OXIDE; OPIATE; PEROXYNITRITE; SECRETIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

AUTOIMMUNE DISEASE; BLOOD FLOW; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); EXERCISE; HOMEOSTASIS; HUMAN; HYDROLYSIS; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; MEMORY; MENTAL CONCENTRATION; MOLECULAR MIMICRY; MYALGIA; NERVE CELL DIFFERENTIATION; NEUROTROPISM; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; THERMOREGULATION;

EID: 1942467943     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.01.012     Document Type: Article

References (62)

1. Harrison's Principles of Internal Medicine. 14th ed. McGraw-Hill; 1998. p. 2483-5.
2. Mandell GL, Douglas RG, Bennett JE. Principles and practice of infectious disease. 5th ed. Churchill Livingstone, Section P.; 2000. p. 1529-34.
3. Peckerman A, La Manca JJ, Dahl KA, Natelson BH, et al. Abnormal impedence cardiography predicts symptom severity in chronic fatigue syndrome. Am J Med Sci 2003;326(2):55-60.
4. Delgado M, Abad C, Martinez C, et al. PACAP in immunity and inflammation. Ann NY Acad Sci 2003;992:141-57.
5. Paul S. Catalytic activity of anti-ground state antibodies, antibody subunits, and human autoantibodies. Appl Biochem Biotechnol 1994;47(2-3):241-53.
6. Brenneman DE, Glazner G, Hill JM, et al. VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting peptide. Ann NY Acad Sci 1998;865:207-12.
7. Gomarez RP, Martinez C, Abad D, et al. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des 2001;7(2):89-111.
8. Zhou CJ, Shioda S, Yada T, et al. PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signalling pathways. Curr Protein Pept Sci 2002;3(4):423-39.
9. Lee FS, Rajagopal R, Kim AH, et al. Activation of Trk neurotrophin receptor signalling by pituitary adenylate cyclase-activating polypeptides. J Biol Chem 2002;277(11):9096-102.
10. Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, Nkappa B, NF-AT, and early growth factors 2/3. J Immunol 2001;166(2):1028-40.
11. Tsutsumi M, Claus TH, Liang Y, et al. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes 2002;51(5):1453-60.
12. Delgado M, Ganea D. VIP and PACAP enhance the in vivo generation of memory TH2 cells by inhibition and peripheral deletion of antigen-specific effectors. Arch Physiol Biochem 2001;109(4):372-6.
13. Delgado M, Jonakait GM, Ganea D. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia 2002;39(2):148-61.
14. Delgado M, Ganea D. Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. Arch Physiol Biochem 2001;109(4):377-82.
15. Vassiliou E, Jiang X, Delgado M, et al. TH2 lymphocytes secrete functional VIP upon antigen stimulation. Arch Physiol Biochem 2001;109(4):365-8.
16. Suzuki N, Shimizu T, Takao M, et al. Neurokinin-1 receptors in the cerebrovascular vasoactive intestinal polypeptide-containing nerves of the rat. Auton Neurosci 2002;95(1-2):103-11.
17. Hamelink C, Tjurmina O, Damadzic R, et al. Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. Proc Natl Acad Sci USA 2002;99(1):461-6.
18. Ganea D, Delgado M. The neuropeptides VIP/PACAP and T cells: inhibitors or activators. Curr Pharm Des 2003;9(12):997-1004.
19. Gomariz RP, Martinez C, Abad C, et al. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des 2001;7(2):89-111.
20. Waschek JA. Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Dev Neurosci 2002;24(1):14-23.
21. Bangale Y, Cavill D, Gordon T, et al. Vasoactive intestinal peptide binding autoantibodies in autoimmune humans and mice. Peptides 2002;23(12):2251-7.
22. Gomariz R. Targeting G protein-coupled A2a adenosine receptors to engineer inflammation in vivo. Int J Biochem Cell Biol 2003;35(4):410-4.
23. Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J Leukoc Biol 2003;73(1):155-64.
24. Brenneman DE, Glazner G, Hill JM, et al. VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Ann NY Acad Sci 1998;865:207-12.
25. Gressens P, Marret S, Bodenant C, et al. Activity-dependent neurotrophic factor-14 requires protein kinase C and mitogen-associated protein kinase activation to protect the developing mouse brain against excitotoxicity. J Mol Neurosci 1999;13(1-2):199-210.
26. Martin M, Otto C, Santamarta MT, et al. Morphine withdrawal is modified in pituitary adenylate cyclase-activating polypeptide type I-receptor-deficient mice. Brain Res Mol Brain Res 2003;110(1):109-18.
27. Jamen F, Persson K, Bertrand G, et al. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose reduced tolerance. Clin Invest 2000;105(9):1307-15.
28. Onoue S, Endo K, Yajima T, et al. Pituitary adenylate cyclase activating polypeptide regulates the basal production of nitric oxide in PC12 cells. Life Sciences 2002;71(2):205-14.
29. Onoue S, Endo K, Yajima T, et al. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide attenuate glutamate-induced nNOS activation and cytotoxicity. Regul Pept 2002;107(1-3):43-7.
30. Pall ML. NMDA sensitisation and stimulation by peroxynitrite, nitric oxide and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity. FASEB J 2002;16(11):1407-17.
31. Bao F, Liu D. Peroxynitrite generated in the rat spinal cord induces neuron death and neurological deficits. Neuroscience 2002;115(3):839-49.
32. Hooper DC, Kean RB, Scott GS, et al. The central nervous system inflammatory response to neurotropic virus infections is peroxynitrite dependent. J Immunol 2001;167(6):3470-7.
33. Thiel VE, Audus KL. Nitric oxide and blood-brain barrier integrity. Antioxid Redox Signal 2001;3(2):273-8.
34. Bested AC, Saunders PR, Logan AC. Chronic fatigue syndrome: neurological findings may be related to blood-brain barrier permeability. Med Hypotheses 2001;57(2):231-7.
35. Kamimura Y, Fujii T, Kojima H, et al. Nitric oxide (NO) synthase mRNA expression and NO production via muscarinic acetylcholine receptor-mediated pathways in the CEM, human leukemic T-cell line. Life Sciences 2003;72(18-19):2151-4.
36. Zviagina TV, Siniachenko OV, Grin' VK, et al. The blood level of nitric oxide metabolites in experimental autoimmune disease during immunosuppressive therapy. Patol Fitziol Eksp Ter 2003;(1):32-3.
37. Imoto A, Inoue R, Tanaka M, et al. Inhibitory NANC neurotransmission in choledocho-duodenal junction of rabbits-possible role of PACAP. J Auton Nerv Syst 1998;70(3):189-99.
38. Thorne RG, Frey 2nd WH. Delivery of neurotrophic factors to the central nervous system:pharmacokinetic considerations. Clin Pharmacokinet 2001;40(12):907-46.
39. Bassan M, Zamostiano R, Davidson A, et al. Complete sequence of a novel protein containing a femtomolar-activlty-dependent neuroprotective peptide. J Neurochem 1999;72(3):1283-93.
40. Leker RR, Teichner A, Grigoriadis N, et al. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 2002;33(4):1085-92.
41. Bagley KC, Abdelwahab SF, Tuskan RG, et al. Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway. J Leukoc Biol 2002;72(5):962-9.
42. Karbownik M, Brzezianska E, Zasada K, et al. Expression of genes for certain enzymes of pyrimidine and Purine salvage pathways in peripheral blood leukocytes collected from patients with Graves' or Hashimoto's disease. J Cell Biochem 2003;89(3):550-5.
43. Kho ND, Montesinos MC, Williams AJ, et al. Th1 cytokines regulate adenosine receptors and their downstream signalling elements in human microvascular endothelial cells. J Immunol 2003;171(8):3991-8.
44. Schnurr M, Toy T, Shin A, et al. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood 2003;(October 9).
45. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in down regulation of inflammation and protection from tissue damage. Nature 2001;414(6866):916-20.
46. Sitkovsky MV. Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 2003;65(4):493-501.
47. Bshesh K, Zhao B, Spight D, et al. The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells. J Leukoc Biol 2002;72(5):1027-36.
48. Montesinos MC, Desai A, Delano D, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48(1):240-7.
49. Liu DM, Cuevas J, Adams DJ. VIP and PACAP potentiation of nicotinic Ach-evoked currents in rat parasympathetic neurons is mediated by G-protein activation. Eur J Neurosci 2000;12(7):2243-51.
50. Shintani N, Hashimoto H, Kunugi A, et al. Desensitisation, surface expression, and glycolisation of a functional, epitope-tagged type1 PACAP (PAC(1)) receptor. Biochem Biophys Acta 2000;1509(1-2):195-202.
51. Steingart RA, Solomon B, Brenneman DE, et al. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J Mol Neurosci 2000;15(3):137-45.
52. Gozes I, Davidson A, Gozes Y, et al. Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Brain Res Dev Brain Res 1997;99(2):167-75.
53. Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J Leukoc Biol 2003;73(1):155-64.
54. Delgado M, Jonakait GM, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia 2002;39(2):148-61.
55. Nagakura A, Miyake-Takagi K, Takagi N, et al. Impairment of adenylyl cyclase and of spatial memory function after microsphere embolism in rats. J Neurosci Res 2002;68(3):363-72.
56. Liu DM, Cuevas J, Adams DJ. VIP and PACAP potentiation of nicotinic Ach-evoked currents in rat parasympathetic neurons is mediated by G-protein activation. Eur J Neurosci 2000;12(7):2243-51.
57. Waterman SA. Autonomic dysfunction in Lambert-Eaton myasthenic syndrome. Clin Auton Res 2001;11:145-54.
58. Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 2002;16(13):1844-6.
59. Bangale Y, Cavill D, Gordon T, et al. Vasoactive intestinal peptide binding autoantibodies in autoimmune humans and mice. Peptides 2002;23(12):2251-7.
60. Delgado M, Munoz-Elias EJ, Gomariz RP, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappaB and IFN regulatory factor1 activation. J Immunol 1999;162(8):4685-96.
61. Shetzline SE, Martiand-Mari C, Reichenbach NL, et al. Structural and functional features of the 37-kDa 2-5A-dependent RnaseL in chronic fatigue syndrome. J Interferon Cytokine Res 2002;22(4):443-56.
62. Amedei A, Bergman MP, Appelmelk BJ, et al. Molecular mimicry between Helicobacter pylori antigens and H+, K+-adenosine triphosphatase in human gastric autoimmunity. J Exp Med 2003;198(8):1147-56.